CER Daily Newsfeed

Value Viewpoint: June 5, 2026

(6/5, Kimberly Westrich, LinkedIn) comments “A new study published in the Journal of Managed Care& Specialty Pharmacy examines how payer decision-makers use patient experience data (PED) in formulary and benefit design. Based on six payer interviews and a survey of 60 decision-makers, the study concludes: ‘Survey responses suggest understanding of PED varies and that payers place low value on PED relative to other information sources, collectively limiting the meaningful use of PED in decision-making. Results also show uptake is impacted by various perceived barriers. Additional training is required on the scientific merit of PED and the rigorous qualitative and quantitative methods used to engage the patient community to collect and leverage PED.’” Full

Beyond Launch: How Real-World Evidence Is Reshaping Value Assessment

(6/8, Katie McCool, The Evidence Base) reports “...From an industry perspective, Shanthy Krishnarajah (Johnson & Johnson) discussed the growing role of comparative RWE in the US Inflation Reduction Act (IRA) Medicare drug price negotiation process. She explained that products selected for negotiation seven to eleven years after launch often face therapeutic landscapes that differ substantially from those studied in pivotal clinical trials. Using direct oral anticoagulants (DOACs) as an example, Krishnarajah noted that while these products were originally compared with warfarin, treatment patterns have evolved considerably over time, increasing the importance of comparative RWE and network meta-analyses.” Full

PhRMA: FDA Lacks Authority To Factor Pricing In Controversial Voucher Pilot, Guardrails Needed

(6/5, James Jarvis, Inside Health Policy) reports “...The Pharmaceutical Research and Manufacturers of America (PhRMA) explicitly warned at a Thursday agency hearing on the voucher that pricing falls outside the FDA's statutory role, and argued drug pricing should not be a factor in eligibility, selection or approval decisions under the pilot. The warning signals the agency's program potentially could be challenged in court.” Subscription Required